By enGenes Biotech…
Subscribe to Supplier
Subscribe to Supplier
enGenes to Present Breakthrough Continuous Bioprocessing Technology at Bioprocessing Summit Boston
Vienna, Austria: – Five months after attending the European BioProcess Summit in Barcelona, recombinant proteins and plasmid DNA specialist CDMO enGenes Biotech will also be a high-profile presence at the USA sister event, the 2025 Bioprocessing Summit in Boston.
This is the first time enGenes has attended the linked summits on both sides of the Atlantic in a single year, partly reflecting its growing influence on bioprocessing science and technology with its patented expression and purification platforms and its leading role in the strategically vital move towards continuous production of proteins and plasmid DNA (pDNA).
Scientific contributor
enGenes CEO and co-founder Dr. Juergen Mairhofer will contribute to the scientific program as part of the conference track on Continuous and Intensive Bioprocessing chaired by Professor David W. Wood of Ohio State University during the first two days (August 18-19).
During the afternoon session of the first day, Dr. Mairhofer will make a presentation on “Fully End-to-End Continuous Production of Recombinant Proteins using E. coli” that will introduce the vital role of the enGenes-eXpress™ growth-decoupled expression platform that provides the foundation for a two-stage chemostat that is genetically stabilized and mitigates adaptive evolution. This two stage chemostat can then be exploited by enGenes-eXcite™ as a cutting-edge technology that further supports continuous manufacturing of biomolecules in E. coli by enabling high yields and scalability from a very small footprint.
High yield and scalability
Dr. Mairhofer will show how these technologies enable sustained, high-yield recombinant protein production while reducing operational footprint, CAPEX, and OPEX and outperforming traditional fed-batch methods. This makes continuous protein production viable for biopharma and industrial biotech, thereby transforming efficiency and scalability.
He will also highlight the advantages gained by combining advanced expression with leading edge machine intelligence modelling and advanced automated real-time process monitoring in the recent ECOnti Project that has achieved significant progress towards continuous protein manufacturing. EnGenes has reunited with ECOnti project partners novasign® and Qubicon® AG in the iCAP Project (Integrated Continuous and Automated Platform for Plasmid Production) looking to revolutionize manufacturing of pDNA.
Contact enGenes
enGenes will use the Summit’s many networking opportunities to share more about its proprietary expression and purification platforms and its involvement in continuous manufacturing bioprocesses.
Dr. Mairhofer commented: “This is a superb opportunity to promote enGenes as a bioprocessing business partner, seek out new collaborations, and share our latest progress, results, findings and knowledge on continuous production using E. coli. We welcome any communications before or during the event to set up face to face meetings.”
About enGenes Biotech
enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading-edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of the current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.
enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes-eXpress™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-eXpress™ has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.
enGenes Biotech offers development and manufacturing services tailored to the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.
Find out more at: https://www.engenes.cc
About Bioprocessing Summit USA 2025
The Bioprocessing Summit convenes more than 1,500 international bioprocessing professionals to share practical solutions for today’s bioprocess challenges. These include including upstream and downstream processing, analytical quality, formulation and stability, cell and gene therapy production, and manufacturing.
Since foundation in 2017, the event has hugely grown in scope and now encompasses 13 conference tracks including around 300 presentations.
The 17th US Bioprocessing Summit is a four day event opening August 18, this time at the Omni Boston Hotel in the city’s Seaport district. Content is also available online with the Virtual Bioprocessing Summit platform.
For 2025, conference programs will explore topics including Cell Culture, Purification, Cell & Gene Therapy, Intensified and Continuous Bioprocessing, and the growing role of AI and Machine Learning in bioprocessing.
The event is organized by Cambridge Healthtech Institute (CHI) with more information available at: https://www.bioprocessingsummit.com
Resources
Click on Contact enGenes to setup one-to-one meeting at the 2025 Bioprocessing Summit in Boston.
Click on Intensified and Continuous Bioprocessing for more on Bioprocessing Summit discussion, including enGenes contribution
Click on enGenes Biotech’s continuous microbial protein expression and purification to learn more.
Click on ECOnti – Accelerated, Low Ecological Footprint, Manufacturing to download factsheet on project.
Related Articles
